| Page 829 | Kisaco Research
 

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics
 

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics

Alzbeta Tuerkova

Head of Computer-Aided Drug Design
Celeris Therapeutics
 

Mary Matyskiela

VP, Molecular Sciences and Lead Discovery
Neomorph

Mary Matyskiela

VP, Molecular Sciences and Lead Discovery
Neomorph

Mary Matyskiela

VP, Molecular Sciences and Lead Discovery
Neomorph
 

Kevin Moreau

Director, Safety Innovation and PROTAC Science Lead
AstraZeneca

Kevin Moreau

Director, Safety Innovation and PROTAC Science Lead
AstraZeneca

Kevin Moreau

Director, Safety Innovation and PROTAC Science Lead
AstraZeneca
 

Kevin Moreau

Director, Safety Innovation and PROTAC Science Lead
AstraZeneca

Kevin Moreau

Director, Safety Innovation and PROTAC Science Lead
AstraZeneca

Kevin Moreau

Director, Safety Innovation and PROTAC Science Lead
AstraZeneca
 

Luc Brunsveld

Co-Founder
Ambagon Therapeutics

Luc Brunsveld

Co-Founder
Ambagon Therapeutics

Luc Brunsveld

Co-Founder
Ambagon Therapeutics
 

Brad Enerson

Executive Director, Head of Preclinical Safety
Kymera Therapeutics

Brad Enerson

Executive Director, Head of Preclinical Safety
Kymera Therapeutics

Brad Enerson

Executive Director, Head of Preclinical Safety
Kymera Therapeutics
 

Andreas Reichel

VP, Head of DMPK, Modelling & Simulations
Bayer

Andreas Reichel

VP, Head of DMPK, Modelling & Simulations
Bayer

Andreas Reichel

VP, Head of DMPK, Modelling & Simulations
Bayer
 

Andreas Reichel

VP, Head of DMPK, Modelling & Simulations
Bayer

Andreas Reichel

VP, Head of DMPK, Modelling & Simulations
Bayer

Andreas Reichel

VP, Head of DMPK, Modelling & Simulations
Bayer